# Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

> **NCT06197581** · NA · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 148 (estimated)

## Conditions studied

- Breast Cancer, Familial Male
- Radiotherapy; Complications
- Chemotherapeutic Toxicity
- Immune Checkpoint Inhibitor
- CDK4/6 Inhibitor
- Trastuzumab
- Pertuzumab
- PARP Inhibitor

## Interventions

- **RADIATION:** Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)

## Key facts

- **NCT ID:** NCT06197581
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-12
- **Primary completion:** 2026-01-15
- **Final completion:** 2027-01-15
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06197581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06197581, "Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06197581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*